2012621诺和力-郑教授.ppt

* This analysis aimed to evaluate the difference in efficacy of using liraglutide early (add-on to ≤1 OAD), or later (add-on to 2 OADs) in the natural history of T2D. Pooled analysis (n=4625) of patients with T2D who participated in LEAD-1 – 6 trials and the Lira-DPP-4 study. Patients were stratified (diet/exercise or 1 OAD [early] vs. 2 OADs [late]). Using liraglutide in patients who were treatment naive or previously taking only 1 OAD achieved superior outcomes than when liraglutide was added to a regimen containing 2 OADs both in terms of change in HbA1c (see earlier) or improvements in markers of beta-cell function (both HOMA-B, shown here, and proinsulin:ratio, next slide) * * * This analysis aimed to evaluate the difference in efficacy of using liraglutide early (add-on to ≤1 OAD), or later (add-on to two OADs) in the natural history of type 2 diabetes. Pooled analysis (n=4625) of patients with type 2 diabetes who participated in the LEAD-1–6 trials and the lira–DPP-4 study. patients were stratified (diet/exercise or one OAD [early] vs. two OADs (late). Using liraglutide in patients who were treatment-na?ve or previously taking only one OAD achieved superior outcomes than when liraglutide was added to a regimen containing two OADs. * * * ANIMATED SLIDE Data are Mean (2SE) and from FAS LOCF. * The LEAD programme: reduction in HbA1c when adding liraglutide Estimated means are obtained from an ANCOVA with treatment, country and previous treatment as fixed effects and baseline value as a covariate. References Marre et al. Diabetic Med 2009;26;268–78 (LEAD-1). Nauck et al. Diabetes Care 2009;32;84–90 (LEAD-2). Garber et al. Lancet 2009;373:473–81 (LEAD-3). Zinman et al. Diabetes Care 2009;32:1224–30 (LEAD-4). Russell-Jones et al. Diabetologia 2009;52:2046–55 (LEAD-5). Buse et al. Lancet 2009;374:39–47 (LEAD-6). * * * 荟萃分析：利拉鲁肽与1个OAD联用可显著改善胰岛分泌质量 胰岛素原:胰岛素比值 p=0.8130 p=0.6504 p=0.0535 早期 (≤1 OAD) 晚期 (2 OADs) 利拉鲁肽 1.8 mg 利拉鲁肽 1.2 mg 安慰剂 Garber et al. Diabetes 2